Therapeutic targets for heart failure: Beyond beta-adrenergic and renin-angiotensin system blockade

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 1, 2008, Pages 37-44

  Iwatsubo, Kousaku ^a   Ishikawa, Yoshihiro ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

MHC; ARK CT; _ARK1; Adenylyl cyclase; Angiotensin (1 7); ASK1; DAA I; FADD; JTV519e; KU 80; Ku70; MST 1; YYI

Indexed keywords

2 AMINO 7 (2 FURANYL) 7,8 DEHYDRO 5(6H)QUINAZOLINE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENOVIRUS VECTOR; ADENYLATE CYCLASE; ADENYLATE CYCLASE 5; ADENYLATE CYCLASE 5 INHIBITOR; ADENYLATE CYCLASE 6; ADENYLATE CYCLASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN[1-7]; APOPTOSIS SIGNAL REGULATING KINASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR KINASE; CALCIUM ION; CASPASE; DES ASPARTATE ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METOPROLOL; MYOSIN HEAVY CHAIN ALPHA; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; PARVOVIRUS VECTOR; PEPTIDE; PEPTIDE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM SIGNALING; CAUSE OF DEATH; CLINICAL PROTOCOL; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE DELIVERY SYSTEM; HEALTH CARE; HEART FAILURE; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VIRAL GENE THERAPY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; CALCIUM SIGNALING; HEART FAILURE; HUMANS; MICE; PATENTS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 38949173967     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008783331661     Document Type: Review

References (103)

1. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106(17):2194-2199.
2. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000; 283(10) 1295-1302.
3. Pritchett AM, Redfield MM. Beta-blockers: new standard therapy for heart failure. Mayo Clin Proc 2002; 77(8): 839-845.
4. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 2003; 362(9386): 772-726.
5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the american college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. Circulation 2005; 112(12): e154-235.
6. Iwatsubo Y, Okumura S, Ishikawa, Y. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets. 2006 Sep; 6(3): 239-247.
7. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human [beta]1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000; 32(5): 817-830.
8. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96(12): 7059-7064.
9. Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000; 101(14): 1707-1714.
10. Xiao R-P, Avdonin P, Zhou Y-Y, Cheng H, et al. Coupling of °2-adrenoceptor to gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 1999; 84(1): 43-52.
11. Iwase M, Bishop SP, Uechi M, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gs alpha overexpression. Circ Res 1996; 78(4): 517-524.
12. Geng YJ, Ishikawa, Y, Vatner DE, et al. Apoptosis of cardiac myocytes in Gsalpha transgenic mice. Circ Res 1999; 84(1): 34-42.
13. Homcy, C.C., Vatner, S.F., Wagner, T., Ishikawa, Y.: US20016333447 ( 2001).
14. Ishikawa Y, Katsushika S, Chen L, Halnon NJ, Kawabe J, Homcy CJ. Isolation and characterization of a novel cardiac adenylylcyclase cDNA. J Biol Chem 1992; 267(19): 13553-1357.
15. Katsushika S, Chen L, Kawabe J, et al. Cloning and characterization of a sixth adenylyl cyclase isoform: types V and VI constitute a subgroup within the mammalian adenylyl cyclase family. Proc Natl Acad Sci USA 1992; 89(18): 8774-8778.
16. Gao MH, Lai NC, Roth DK et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 1999; 99(12): 1618-1622.
17. Roth DM, Gao MH, Lai NC, et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 1999; 99(24): 3099-3102.
18. Roth DM, Bayat H, Drumm JD, et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 2002; 105(16): 1989-1994.
19. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350(7):647-654.
20. Hammond, H.K., Insel, P.A.: WO9810085 (1998).
21. Ishikawa, Y.: US5578481 (1996).
22. Okumura S, Kawabe J, Yatani A, et al. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 2003; 93(4): 364-371.
23. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. Faseb J 1990; 4(11):2881-2889.
24. Okumura S, Vatner DE, Kurotani R, et al. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 2007; 116(16): 1776-1783.
25. Vatner, S.F.: US20060252774 (2006).
26. Yan L, Vatner DE, O'Connor JP, et al. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2007; 130(2): 247-258.
27. Onda T, Hashimoto Y, Nagai M, et al. Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 2001; 276(51): 47785-47793.
28. Iwatsubo K, Minamisawa S, Tsunematsu T, et al. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 2004; 279(39): 40938-40945.
29. Levy DE, Bao M, Cherbavaz DB, et al. Metal coordination-based inhibitors of adenylyl cyclase: novel potent P-site antagonists. J Med Chem 2003; 46(11): 2177-2186.
30. Iwatsubo K, Tsunematsu T, Ishikawa Y. Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. Expert Opin Ther Targets 2003; 7(3): 441-451.
31. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282(5394): 1669-1675.
32. Englund PT, Huberman JA, Jovin TM, Kornberg A. Enzymatic synthesis of deoxyribonucleic acid. XXX Binding of triphosphates to deoxyribonucleic acid polymerase. J Biol Chem 1969; 244(11): 3038-3044.
33. Artymiuk PJ, Poirrette AR, Rice DW, Willett P. A polymerase I palm in adenylyl cyclase? Nature 1997; 388(6637): 33-34.
34. Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature 1997; 386(6622): 247-253.
35. Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsα.GTPgammaS. Science 1997; 278(5345):1907-1916.
36. Tang WJ, Gilman AG. Construction of a soluble adenylyl cyclase activated by Gs alpha and forskolin. Science 1995; 268(5218): 1769-1772.
37. Nagai, M., Onda, T.: JP02338467 (2002).
38. Tesmer JJ, nbsp, G, Sunahara RK, et al. Two-metal-ion catalysis in adenylyl cyclase. Science 1999; 285(5428): 756-760.
39. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998; 98(13): 1329-1334.
40. Okumura S, Takagi G, Kawabe J, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 2003; 100(17): 9986-9990.
41. Bristow MR. {beta} -adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101(5): 558-569.
42. Koch WJ, Inglese J, Stone WC, Lefkowitz RJ. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem 1993; 268(11): 8256-8260.
43. Levy, D., Marlowe, C., Kane-Maguire, K., Scarborough, R.M.: US20020068745 (2002).
44. Penn RB, Pronin AN, Benovic JL. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc Med 2000; 10(2): 81-89.
45. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995; 268(5215): 1350-1353.
46. Akhter SA, Eckhart AD, Rockman HA, Shotwell K, Lefkowitz RJ, Koch WJ. in vivo Inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. Circulation 1999; 100(6): 648-653.
47. Anderson KM, Eckhart AD, Willette RN, Koch WJ. The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Hypertension. 1999; 33(1 Pt 2): 402-407.
48. Rockman HA, Chien KR, Choi D-J, et al. Expression of a beta - adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proceed Nat Acad Sci 1998; 95(12). 7000-7005.
49. Ungerer M, Kessebohm Y, Kronsbein K, Lohse MJ, Richardt G. Activation of beta-adrenergic receptor, kinase during myocardial ischemia. Circ Res 1996; 79(3): 455-460.
50. Choi D-J, Koch WJ, Hunter JJ, Rockman HA. Mechanism of beta - adrenergic receptor desensitization in cardiac hypertrophy is increased beta -adrenergic receptor kinase. J Biol Chem 1997; 272(27): 17223-17229.
51. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87(2): 454-463.
52. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockmart HA. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proceed Nat Acad Sci 2001; 98(10): 5809-5814.
53. Rockman HA, Choi D-J, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proceed Nat Acad Sci 1996; 93(18): 9954-9959.
54. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001; 107(8): 967-974.
55. Akhter SA, Skaer CA, Kypson AP, et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 1997; 94(22): 12100-12105.
56. William ML, Hats JA, Schroder J, et al. Targeted β-adrenergic receptor kinase (ßark1) inhibition by gene transfer in failing human hearts. Circulation 2004; 109(13): 1590-1593.
57. Eckhart AD, Koch WJ. Expression of a beta-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes. Mol Ther 2002; 5(1): 74-79.
58. White DC, Hats JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA 2000; 97(10): 5428-5433.
59. Shah AS, White DC, Emani S, et al. in vivo Ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103(9): 1311-1316.
60. Sim MK, Choo MHH, Qiu XS. Degradation of angiotensin I to [des-Asp1]angiotensin I by a novel aminopeptidase in the rat hypothalamus. Biochem Pharmacol 1994; 48(5): 1043-1046.
61. Hammond, H.K., Insel, P.A., Ping, P., Post, S.R., Gao, M.: US20016306830 (2001).
62. Sim MK, Radhakrishnan R. Novel central action of des-Asp-angiotensin I. Eur J Pharmacol 1994; 257(1-2): R1-R3.
63. Sim MK, Min L. Effects of des-Asp-angiotensin I on experimentally-induced cardiac hypertrophy in rats. Inter J Cardiol 1998; 63(3): 223-227.
64. Min L, Sim MK, Xu XG. Effects of des-aspartate-angiotensin I on angiotensin. II-induced incorporation of phenylalanine and thymidine in cultured rat cardiomyocytes and aortic smooth muscle cells. Reg Pep 2000; 95(1-3): 93-97.
65. Wen Q, Sim M-K, Tang F-R. Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart. Reg Pep 2004; 120(1-3): 149-153.
66. Rufaihah AJ, Haider HK, Sim KM, et al. Cardioprotective effect of des-Aspartate-angiotensin-I (DAA-I) on cytokine gene expression profile in ligation model of myocardial infarction. Life Sci 2006; 78(12): 1341-1351.
67. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31(2): 699-705.
68. Sim, M.K.: US20030017989 (2003).
69. Roks AJ, van Geel PP, Pinto YM, et al. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999; 34(2): 296-301.
70. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996: 27(3 Pt 2): 523-528.
71. Loot AE, Roks AJM, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105(13): 1548-1550.
72. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1•) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33(1): 207-211.
73. Roks, A.J.M., Henning, R.H., van Gilst, W.H., van der Graaf, A.C.: US20050119180 (2005).
74. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 2002; 40(6): 847-852.
75. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275(5296): 90-94.
76. Tijsma, E.J., Driessen-Levels, A,, Hendriks, M.: US20077176261 (2007).
77. Hirotani S, Otsu K, Nishida K, et al. Involvement of nuclear factor-{kappa}b and apoptosis signal-regulating kinase 1 in g-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105(4): 509-515.
78. Yamaguchi O, Higuchi Y, Hirotani S, et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proceed Nat Acad Sci 2003; 100(26): 15883-15888.
79. Watanabe T, Otsu K, Takeds. T, et al. Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death. Biochem Biophys Res Com 2005; 333(2): 562-567.
80. Hikoso S, Ikeda Y, Yamaguchi O, et al. Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via tramoronary gene trawfer. J Am Coll Cardiol 2007; 50(5): 453-462.
81. Creasy CL, Chernoff J. cloning and characterization of a human protein kinase with homology to ste20. J Biol Chem 1995; 270(37): 21695-21700.
82. Otsu, K., Nishida, K., Yamaguchi, O., Higuchi, Y., Ichijo, H.: US20070167386 (2007).
83. Taylor LK, Wang H-CR, Erikson RL. Newly identified stress-responsive protein kinases, Krs-1 and Krs-2. Proceed Nat Acad Sci 1996; 93(19):10099-10104.
84. Dan I, Watanabe NM, Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol 2001; 11(5): 220-230.
85. Ura S, Masuyama N, Graves JD, Gotoh Y. MST1-JNK promotes apoptosis via caspase-dependent and independent pathways. Genes Cells 2001; 6(6): 519-30.
86. Yamamoto S, Yang G, Zablocki D, et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest 2003; 111(10):1463-1474.
87. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81(4): 505-512.
88. Vatner, S.F., Sadoshima, J.: US20040213794 (2004).
89. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induccd apoptosis. J Biol Chem 1996, 271(9): 4961-4965.
90. Chao W, Shen Y, Li L, Rosenzweig A. Importance of FADD signaling in serum deprivation- and hypoxia-induced cardiomyocyte apoptosis. J Biol Chem 2002; 277(35): 31639-31645.
91. 2+ homeostasis and disease. Cell Calcium 2000; 28(i): 1-21.
92. Rosenzweig, A., Chao, W.: US20060148735 (2006).
93. Marks AR. Clinical implications of cardiac ryanodine receptor/calcium release channel mutations linked to sudden cardiac death. Circulation 2002; 106(1): 8-10.
94. Yano M, Kobayashi S, Kohno M, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003; 107(3): 477-484.
95. Wehrens XHT, Lehnart SE, Reiken S, et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle fraction in heart failure. Proceed Nat Acad Sci 2005; 102(27): 9607-9612.
96. Abraham WT, Gilbert EM, Lowes BD, et al. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 2002; 8(11): 750-760.
97. Marks, A.R., Landry, D.W., Deng, S., Cheng, Z.Z., Lehnart, S.E.: US20070049572 (2007).
98. Tardiff JC, Hewett TE, Factor SM, Vikstrom. KL, Robbins J, Leinwand LA. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 2000; 278(2): H412-419.
99. Tokunou T, Shibata R, Kai H, et al. Apoptosis induced by inhibition of cyclic amp response element-binding protein in vascular smooth muscle cells. Circulation 2003; 108(10): 1246-1252.
100. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105(4): 446-451.
101. Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 1999; 236(2): 197-208.
102. Sucharov CC, Helmke SM, Langer SJ, Perryman MB, Bristow M, Leinwand L. The ku protein complex interacts with yy1, is upregulated in human heart failure, and represses α myosin heavy-chain gene expression. Mol Cell Biol 2004; 24(19): 8705-8715.
103. Kyte J. Molecular considerations relevant to the mechanism of active transport. Nature. 1981; 292(5820): 201-204.